Share Name Share Symbol Market Type Share ISIN Share Description
Yourgene Health Plc LSE:YGEN London Ordinary Share GB00BN31ZD89 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.75 -3.85% 18.75 2,250,774 14:13:04
Bid Price Offer Price High Price Low Price Open Price
18.50 19.00 19.50 18.75 19.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 8.88 3.39 1.00 18.8 117
Last Trade Time Trade Type Trade Size Trade Price Currency
17:06:22 O 17,500 18.75 GBX

Yourgene Health (YGEN) Latest News

More Yourgene Health News
Yourgene Health Takeover Rumours

Yourgene Health (YGEN) Discussions and Chat

Yourgene Health Forums and Chat

Date Time Title Posts
20/5/202007:42YourGene to Infinity2,121
04/5/202008:06Partnership with Novacyt 2
30/3/202008:20Yourgene Health at the UK Investor Show3

Add a New Thread

Yourgene Health (YGEN) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Yourgene Health trades in real-time

Yourgene Health (YGEN) Top Chat Posts

Yourgene Health Daily Update: Yourgene Health Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker YGEN. The last closing price for Yourgene Health was 19.50p.
Yourgene Health Plc has a 4 week average price of 17.50p and a 12 week average price of 7.25p.
The 1 year high share price is 23.50p while the 1 year low share price is currently 7.25p.
There are currently 624,331,197 shares in issue and the average daily traded volume is 3,828,436 shares. The market capitalisation of Yourgene Health Plc is £117,062,099.44.
ngen yap: I am really interested in the Thermo warrants. Because of our share price position, 2 of the 3 tranches have hit 50% above their exercise prices for a period now. It doesn't stipulate what period is contained in the agreement, but YGEN have the ability to force conversion or cancellation of the warrants. Either options are a positive. Typically, it is 30 days, we must be near that......tell us Mr Rees!
the abbot: In terms of results, not just theory, I think you will start to see that this week in the share price.
the abbot: suggest you look at the Market Cap not just the share price £120m. Revenues for the year ended 31 March 2020 were £16.6m (2019: £8.9m), up 86% compared to the previous year, and does not include £0.4m of orders for March that fell into the new financial year due to COVID-19 transport restrictions. The revenue increase reflects organic growth of approximately 36%; 11 months contribution from Elucigene Diagnostics, acquired on 26 April 2019; and three weeks' contribution from the Company's French NIPT distribution business, acquired on 10 March 2020.
danvestment: Thanks, yes I was aware of their involvement - it would be nice to know if their order book was 1000 or 1 million units. In that way I can get a gauge on their share price prospects. None the less, they seem strong regardless of additional COVID support. Have a good week.
ngen yap: Looking at Novacyt as reference point, their share price action truly motored when they announced some volume / financials to the tests. We should expect these in our next update. I imagine they want to coincide FY trading update with first delivery of Novacyt tests and/or NHS lab testing support. Probably explains delay versus last year of trading update. Patience, our day will come. Mind you, we haven't done badly share price wise, just not as well with the 25th March included.
ngen yap: The magnitude of today's news will translate into further rises, when YGEN updates us with financials attached. Much like Novacyt did over the course of 4 weeks, and share price went from 15p to 150p! What truly amazed me with today's news is how flexible our manufacturing capabilities, and its capacity. Also very reassuringly, existing core business proving resilient. I really liked YGEN, now I love it.
melton john: YGEN price holding up with nearly 11 million shares traded at 35% premium to opening price. Stale bulls taking profits and new money taking their places. Should be a good floor for the future and the story is just starting to unfold imo. I bought more on the news. Still only on a P/E of 16 according to ADVFN.
twix386: On balance I expect a retrace of our share price tomorrow so down on the day. Be surprised if we build on Fridays rise.For Frenchy. Having freed up funds I am looking to buy 75000 if/When we retrace. fwiw I expect it will drop lower at some point after I purchase but id rather buy and hold down here for eventual Covid resolution and our q2 illumina platform delivery. This panic will pass and I know it's folly to try to time the bottom or the top. I can buy at unimaginable prices just a week ago. That'll do with a dose of patience and ignoring fools who crow when/if the price goes lower for a while.
pedr01: Initial forward multiples always appear high when a company just goes into profit for the first time, since profit is low (non existent) and share price has risen in anticipation. You are paying for the anticipated future acceleration of profits relative to current share price once the company goes into profitability. At the moment peeps are paying 16.75p for forecast zero earnings. Ignoring the sector, the current going rate is; Forecast forward p/e for 2020 is infinity (forecast loss) Forecast forward p/e for 2021 is 167 (16.75/0.1p) Forecast for 2021 is 0.1p Forecast forward p/e for 2022 is 56 (16.75/0.3p) Forecast for 2022 is 0.3p If ngen numbers come to fruition a forward p/e of 40 will seem cheap,cheap, cheap ... All IMHO of course ...
scotty1: Another good reasoned post from notaflipper over the road. Obviously there's a lot of information to take in so let's go through the deal the circa 20% share expansion and TW's valuation. If I am honest TW's reaction seems very stage managed. Having known the Trading Statement date he was probably aware hence making this his 'nap' tick for end of April. Otherwise him, and other backroom commentators, expectations of a spike would have optimistically been based on the TS alone. Elucigene has launched 36 commercial products. Its main product categories cover Cystic Fibrosis Kits, Rapid Aneuploidy Analysis, Reproductive Health, Genetic Disease Diagnosis. The business was founded 20 years ago by pharmaceutical giant AstraZeneca and has changed hands several times since. In October 2013 the business was established as an independent company, when Scott Higgins, 55, and Mike Webb, 60, led a management buyout backed by Percipient Capital.Gross. Elucigene had a turnover of £3.6m in FY2018 with a with a cost of sales of £500k. This means a Cash Generative business already of surplus £3.1m. Cash is £1.3m, gross and operating profits £0.6 million and net cash is £0.4 million . The company plans to expand internationally and sees South America and India as key markets for its growth. More importantly for YGEN holders it plans to expand into the US this year The Enlarged company though it will have 574,418,577 shares after and potentially a further 11,550,000 if TMO further subscribe will have also the following: Elucigene's product offering plus IONA test plus further product expansions - no long overdue to be announced - such as pre-implantation genetic screening (PGS), Rhesus disease screens, BRAC1 screen and Illumina's version of the IONA test. In total the product portfolio now will be close to 40. The Enlarged company would have sales of £12.5 million in FY2018. Elucigene have no public sales forecasts so even if we assume they're flat at £3.6m the Enlarged Company will have improved sales forecasts of £16.1M in FY2020E and £20.8M in FY2021E. Break-even to be achieved this year. On a fully diluted basis of 586m shares at 17p share price the market capitalisation would be £99.6m. With currently 459m at a proposed share price of 20p the market capitalisation would be £91.8m. TW HAS UPGRADED HIS VALUATION. To be fair to TW the reason his share price targets fail is there's not been much volume. Much of the share price movement has been driven by Steve Myers. With swing traders making up 2/3p movement. Hence the tedious trading pattern between 13.5 to 10.5p since February. On Friday we saw 6m shares traded this bodes well in addition to new investors and a 12 month lock-in period for new shares. Even at 17p this would be very low. With sales of £16m in FY2020E the current share price on a fully diluted basis is £70m. This gives a 4.5 EV/sales multiple of 4.4. At 17p an EV of £99m would be 6. Considering the test volumes will now be in excess of 100k an EV/sales multiple closer to 10x would be fairer. These figures are also conservative because we do not know Elucigene's sales forecasts or the new test volumes expected by new products this year. I suspected that the TW's mood will be come better in the next week or so with a revised broker rating and research note which may be accompanied by further potentially further announcements. Thereafter a stage managed increase in target will predictably ensue.
Yourgene Health share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Yourgene H..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200530 16:35:05